The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.
 
Mahmut Gumus
Honoraria - MSD Oncology (Inst)
Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Lilly (Inst); Novartis (Inst); Roche
Speakers' Bureau - MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Chieh-I Chen
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Cristina Ivanescu
Employment - IQVIA
Research Funding - Regeneron (Inst)
 
Saadettin Kilickap
Consulting or Advisory Role - MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Speakers' Bureau - MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
 
Igor Bondarenko
No Relationships to Disclose
 
Mustafa Ozguroglu
Honoraria - Astellas Pharma; Janssen Oncology (Inst); Novartis
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Miranda Gogishvili
No Relationships to Disclose
 
Haci M. Turk
No Relationships to Disclose
 
Irfan Cicin
Consulting or Advisory Role - Abbvie (Inst); Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Nobelpharma (Inst); Novartis/Ipsen (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst); Teva
Speakers' Bureau - Abdi Ibrahim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
James Harnett
Employment - Pfizer; Regeneron
Stock and Other Ownership Interests - Pfizer; Regeneron
 
Vera Mastey
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Ulrike Naumann
Employment - IQVIA
Consulting or Advisory Role - IQVIA
 
Matthew Reaney
Employment - Sanofi
 
Gerasimos Konidaris
Employment - Sanofi
 
Medha Sasane
Employment - Sanofi
Leadership - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Keri Brady
Employment - CVS Health (I); Sanofi
Stock and Other Ownership Interests - CVS Health (I)
 
Siyu Li
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Giuseppe Gullo
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Petra Rietschel
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Ahmet Sezer
Honoraria - Amgen (Inst); pfizer (Inst); Roche (Inst)
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Pfizer; Roche
Research Funding - Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche